NewsBenzingaJupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease Jupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease Benzinga 2026.10.06 15:18 (GMT+0) Open on Benzinga Other news B of A Securities Maintains Buy on MongoDB, Lowers Price Target to $450 Bath & Body Works Shares Rise Despite Weak Holiday Outlook as Q3 Earnings Beat Estimates StoneX Initiates Coverage On NXP Semiconductors with Buy Rating, Announces Price Target of $340 B of A Securities Maintains Neutral on Roblox, Raises Price Target to $48 What's Going On With Baker Hughes Stock Thursday? B of A Securities Maintains Buy on NiSource, Raises Price Target to $48